Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

(2013) Jenny M. Norlin et al.   DERMATOLOGY

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Biologics for psoriasis: current evidence and future use

(2012) C.E.M. Griffiths   BRITISH JOURNAL OF DERMATOLOGY

A framework for improving the quality of care for people with psoriasis

(2012) M. Augustin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Burden of Moderate to Severe Psoriasis

(2012) Giovanna Raho et al.   PHARMACOECONOMICS

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

(2011) J.M. Norlin et al.   BRITISH JOURNAL OF DERMATOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

(2008) M. Augustin et al.   DERMATOLOGY

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: Results from a randomized, controlled Phase III study

(2008) Dennis A Revicki et al.   Health and Quality of Life Outcomes

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening

(2008) Alexa B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY